21 reports of this reaction
2.3% of all ISOPROTERENOL HYDROCHLORIDE reports
#6 most reported adverse reaction
CARDIOGENIC SHOCK is the #6 most commonly reported adverse reaction for ISOPROTERENOL HYDROCHLORIDE, manufactured by Cipla USA Inc.. There are 21 FDA adverse event reports linking ISOPROTERENOL HYDROCHLORIDE to CARDIOGENIC SHOCK. This represents approximately 2.3% of all 894 adverse event reports for this drug.
Patients taking ISOPROTERENOL HYDROCHLORIDE who experience cardiogenic shock should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIOGENIC SHOCK is a less commonly reported adverse event for ISOPROTERENOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to cardiogenic shock, the following adverse reactions have been reported for ISOPROTERENOL HYDROCHLORIDE:
The following drugs have also been linked to cardiogenic shock in FDA adverse event reports:
CARDIOGENIC SHOCK has been reported as an adverse event in 21 FDA reports for ISOPROTERENOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIOGENIC SHOCK accounts for approximately 2.3% of all adverse event reports for ISOPROTERENOL HYDROCHLORIDE, making it a notable side effect.
If you experience cardiogenic shock while taking ISOPROTERENOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.